AKBA insider trading
NasdaqCM HealthcareAkebia Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Company website: www.akebia.com
AKBA insider activity at a glance
FilingIQ tracks 332 insider transactions for AKBA in filings since Jan 5, 2015. The most recent transaction is dated Aug 6, 2026.
Across the full history, 8 open-market purchases
and 152 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AKBA insider trades is 57.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AKBA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AKBA?
- FilingIQ tracks 332 Form 4 insider transactions for AKBA (Akebia Therapeutics, Inc.), covering filings from Jan 5, 2015 onwards. 1 of those are dated within the last 90 days.
- Are AKBA insiders net buyers or net sellers?
- Across the full Form 4 history for AKBA, 8 transactions (2%) were open-market purchases and 152 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AKBA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AKBA in?
- Akebia Therapeutics, Inc. (AKBA) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $321.09M.
Methodology & sources
Every AKBA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.